Category: Laser-sharp Research

Modulight Spotlights: LASER-SHARP RESEARCH – April 2026

Laser-sharp Research / 689 nm, cancer, immunotherapy, IR700, laser therapy, laser-sharp research, ML7710, peptides, Photoimmunotherapy, targeted therapies, tumor / April 27, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – April 2026 This month we are pleased to highlight new interesting article by Naoya Kondo and the team at Kansai Medical University in Japan. They developed a cancer cell-targeted photoimmunotherapy compound consisting of IR700 photoabsorber conjugated to bicyclic peptide. Use of small peptide could speed drug clearance from the body [...]

Modulight Spotlights: LASER-SHARP RESEARCH – April 2026 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – March 2026

Laser-sharp Research / chemo resistance, in vitro, in vivo, laser-sharp research, ML7710, ML8500, National Cancer Institute, ovarian cancer, peritoneal carcinoma, photoimmunoconjugates, Photoimmunotherapy, targeted therapies, University of Maryland / March 12, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – March 2026 The development of chemoresistance presents a major challenge in treating peritoneal metastasis, which often occurs in advanced ovarian cancer. To tackle this, Kaitlyn Moore and teams at University of Maryland and National Cancer Institute evaluated photoimmunotherapy as a solution to inhibit a drug efflux pump on cancer cells

Modulight Spotlights: LASER-SHARP RESEARCH – March 2026 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – February 2026

Laser-sharp Research / antibodies, Cancer therapy, laser therapy, laser-sharp research, ML7710, next generation therapies, peptides, Photoimmunotherapy, tumor / February 27, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – February 2026 This month, we are highlighting promising work by Professor Hirofumi Hanaoka’s team at Kansai Medical University, Photo-ImmunoTherapy Research Institute. They developed a novel peptide-based photoimmunotherapy drug that targets PD-L1, which is expressed on many types of cancer cells. Preclinical experiments showed significant suppression of tumor growth and an

Modulight Spotlights: LASER-SHARP RESEARCH – February 2026 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – January 2026

Laser-sharp Research / apoptosis, BPD, cancer, ferroptosis, in vitro, in vivo, laser-sharp research, light activation, ML6600, ovarian cancer, Photoimmunotherapy, photosensitizer / January 28, 2026

Modulight Spotlights: LASER-SHARP RESEARCH – January 2026 The highlight of the month goes to teams of researchers led by Prof. Imran Rizvi at University of North Carolina at Chapel Hill. Their latest publication shows that certain light-activated therapy with BPD photosensitizer and ML6600 laser can induce ferroptosis-like cell death, including formation of lipid peroxides, in

Modulight Spotlights: LASER-SHARP RESEARCH – January 2026 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – December 2025

Laser-sharp Research / imaging, in vitro, in vivo, laser-sharp research, ML6600, multi-wavelength, oxygen, Photodynamic therapy, treatment guidance, treatment monitoring, tumor, ultrasound / December 30, 2025

Deeksha Sankepalle and the group at Tufts University, USA developed an advanced multi-wavelength photoacoustic imaging system. It integrates a pulsed, tunable laser with an ultrasound acquisition platform to provide functional 3D imaging. The system enables real-time, non-invasive, high-resolution imaging of tumor vasculature by tracking oxygen saturation in the tumor.

Modulight Spotlights: LASER-SHARP RESEARCH – December 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – November 2025

Laser-sharp Research / cancer, chemotherapy, drug delivery, glioblastoma, in vitro, laser-sharp research, ML8500, multidrug resistance, photoactivated chemotherapy, Photoimmunotherapy, preclinical, therapy resistance, tumor, University of Maryland, verteporfin / November 19, 2025

Modulight Spotlights: LASER-SHARP RESEARCH – November 2025 We are delighted to highlight new exciting study by Rahman et al. from Dr. Huang-Chiao Huang’s lab at University of Maryland. Multidrug resistance remains a significant barrier to successful chemotherapy outcomes for cancer patients, often caused by active pumping of chemotherapeutics outside of cancer cells. Hence, the team

Modulight Spotlights: LASER-SHARP RESEARCH – November 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – October 2025

Laser-sharp Research / breast cancer, immunotherapy, laser-sharp research, ML7710, myeloma, oral cancer, Photoimmunotherapy, preclinical, T cells / October 29, 2025

This month we are highlighting exciting findings by S. Takao et al. from Hisataka Kobayashi’s lab at the National Cancer Institute, NIH. Published in Cancer Letters, the study shows that near-infrared photoimmunotherapy can destroy cancer cells by targeting intercellular adhesion molecule-1.

Modulight Spotlights: LASER-SHARP RESEARCH – October 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – September 2025

Laser-sharp Research / cancer, immunotherapy, in vitro, in vivo, laser-sharp research, ML7710, noveltherapies, Photoimmunotherapy, targeted therapy / September 2, 2025

Published in journal Cancer Medicine, the study shows that the therapeutic effect of photoimmunotherapy is highly dependent on the used light irradiation conditions. Application of the ML7710 medical laser at different durations and powers resulted in highest anti-tumor effect with increased light dose but lowering fluence rate below what is currently used in clinic.

Modulight Spotlights: LASER-SHARP RESEARCH – September 2025 Read More »

Modulight Spotlights: LASER-SHARP RESEARCH – August 2025

Laser-sharp Research / breast cancer, cancer, immunotherapy, in vitro, in vivo, laser-sharp research, ML7710, NIH, Photoimmunotherapy, targeted therapy / August 18, 2025

Laser-sharp research of the month is by Furusawa et al. at Center for Cancer Research, National Cancer Institute, USA. The discovery, published in Annals of Medicine, showed the potential of photoimmunotherapy for treating breast cancer. To expand the usefulness of photoimmunotherapy outside the clinically approved head & neck indication, the new therapy targeted epithelial cell adhesion molecule in breast cancer.

Modulight Spotlights: LASER-SHARP RESEARCH – August 2025 Read More »